Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings

Bibliography

• HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. (1997) 337(11):725-733.
   PubMed Web of Science ®Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. (1997) 337(11):734-739.
   PubMed Web of Science ®Google Scholar
• YEH KC, DEUTSCH PJ, HADDIX H et al.: Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. (1998) 42(2):332-338.
   PubMed Web of Science ®Google Scholar
• VACCA JP, DORSEY BD, SCHLEIF WA et al.: L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA (1994) 91(9):4096-4100.
   PubMed Web of Science ®Google Scholar
• STEIN DS, FISH DG, BILELLO JA et al.: A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 10(5):485-492.
   PubMed Web of Science ®Google Scholar
• Crixivan (Indinavir Sulphate) Capsules. Package Insert. Merck & Co., Inc.
   Google Scholar
• KEMPF DJ, MARSH KC, KUMAR G et al.: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. (1997) 41(3):654-660.
   PubMed Web of Science ®Google Scholar
• HSU A, GRANNEMAN GR, CAO G et al.: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42(11):2784-2791.
   PubMed Web of Science ®Google Scholar
• SAAH AJ, WINCHELL GA, NESSLY ML et al.: Pharmacokinetic profile and tolerability of indinavir–ritonavir combinations in healthy volunteers. Antimicrob. Agents Chemother. (2001) 45(10):2710-2715.
   PubMed Web of Science ®Google Scholar
• VAN HEESWIJK RP, VELDKAMP AI, HOETELMANS RM et al.: The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS (1999) 13(14):F95-F99.
   PubMed Web of Science ®Google Scholar
• GHOSN J, LAMOTTE C, AIT-MOHAND H et al.: Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 17(2):209-214.
   PubMed Web of Science ®Google Scholar
• CRESSEY TR, LEENASIRIMAKUL P, JOURDAIN G et al.: Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J. Antimicrob. Chemother. (2005) 55(6):1041-1044.
   PubMed Web of Science ®Google Scholar
• BURGER DM, HUGEN PW, VAN DER ENDE ME et al.: Once-daily indinavir plus ritonavir: preliminary results of the PIPO study. AIDS (2000) 14(16):2621-2623.
   PubMed Web of Science ®Google Scholar
• MUELLER BU, SLEASMAN J, NELSON RP Jr et al.: A Phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics (1998) 102(1 Pt 1):101-109.
   PubMed Web of Science ®Google Scholar
• GATTI G, VIGANO A, SALA N et al.: Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (2000) 44(3):752-755.
   PubMed Web of Science ®Google Scholar
• FLETCHER CV, BRUNDAGE RC, REMMEL RP et al.: Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob. Agents Chemother. (2000) 44(4):1029-1034.
   PubMed Web of Science ®Google Scholar
• VAN ROSSUM AM, NIESTERS HG, GEELEN SP et al.: Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections. J. Pediatr. (2000) 136(6):780-788.
   PubMed Web of Science ®Google Scholar
• BURGER DM, VAN ROSSUM AM, HUGEN PW et al.: Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother. (2001) 45(3):701-705.
   PubMed Web of Science ®Google Scholar
• VAN ROSSUM AM, DE GROOT R, HARTWIG NG et al.: Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection. AIDS (2000) 14(14):2209-2210.
   PubMed Web of Science ®Google Scholar
• BERGSHOEFF AS, FRAAIJ PL, VAN ROSSUM AM et al.: Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir. Ther. (2003) 8(3):215-222.
   PubMed Web of Science ®Google Scholar
• CHADWICK EG, RODMAN JH, SAMSON P et al.: Antiviral Activity, Tolerance and Pharmacokinetics of Indinavir with Two Doses of Ritonavir as Salvage Therapy in Children. 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2003): Abstract 875.
   Google Scholar
• PLIPAT N, CRESSEY TR, VANPRAPAR N et al.: Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr. Infect. Dis. J. (2007) 26(1):86-88.
   PubMed Web of Science ®Google Scholar
• FLEXNER C: HIV-protease inhibitors. N. Engl. J. Med. (1998) 338(18):1281-1292.
   PubMed Web of Science ®Google Scholar
• SCHON A, DEL MAR INGARAMO M, FREIRE E: The binding of HIV-1 protease inhibitors to human serum proteins. Biophys. Chem. (2003) 105(2-3):221-230.
   PubMed Web of Science ®Google Scholar
• ANDERSON PL, BRUNDAGE RC, BUSHMAN L et al.: Indinavir plasma protein binding in HIV-1-infected adults. AIDS (2000) 14(15):2293-2297.
   PubMed Web of Science ®Google Scholar
• BALANI SK, ARISON BH, MATHAI L et al.: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. (1995) 23(2):266-270.
   PubMed Web of Science ®Google Scholar
• BALANI SK, WOOLF EJ, HOAGLAND VL et al.: Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. (1996) 24(12):1389-1394.
   PubMed Web of Science ®Google Scholar
• CHIBA M, HENSLEIGH M, NISHIME JA et al.: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. (1996) 24(3):307-314.
   PubMed Web of Science ®Google Scholar
• JUSTESEN US, ANDERSEN AB, KLITGAARD NA et al.: Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin. Infect. Dis. (2004) 38(3):426-429.
   PubMed Web of Science ®Google Scholar
• JARURATANASIRIKUL S, SRIWIRIYAJAN S: Effect of indinavir on the pharmacokinetics of rifampicin in HIV- infected patients. J. Pharm. Pharmacol. (2001) 53(3):409-412.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, GALLICANO KD: Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med. (2001) 344(13):984-996.
   PubMed Web of Science ®Google Scholar
• KRAFT WK, MCCREA JB, WINCHELL GA et al.: Indinavir and rifabutin drug interactions in healthy volunteers. J. Clin. Pharmacol. (2004) 44(3):305-313.
   PubMed Web of Science ®Google Scholar
• HAMZEH FM, BENSON C, GERBER J et al.: Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin. Pharmacol. Ther. (2003) 73(3):159-169.
   PubMed Web of Science ®Google Scholar
• DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services (DHHS), NIH, USA (2006).
   Google Scholar
• DE WIT S, DEBIER M, DE SMET M et al.: Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (1998) 42(2):223-227.
   PubMed Web of Science ®Google Scholar
• PURKINS L, WOOD N, KLEINERMANS D et al.: No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):62-68.
   PubMed Web of Science ®Google Scholar
• GLESBY MJ, ABERG JA, KENDALL MA et al.: Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin. Pharmacol. Ther. (2005) 78(2):143-153.
   PubMed Web of Science ®Google Scholar
• KOSEL BW, AWEEKA FT, BENOWITZ NL et al.: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS (2002) 16(4):543-550.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, BURSTEIN AH, CHAITT D et al.: Indinavir concentrations and St John’s wort. Lancet (2000) 355(9203):547-548.
   PubMed Web of Science ®Google Scholar
• PISCITELLI SC, FORMENTINI E, BURSTEIN AH et al.: Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy (2002) 22(5):551-556.
   PubMed Web of Science ®Google Scholar
• MERRY C, BARRY MG, RYAN M et al.: Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS (1999) 13(15):F101-F107.
   PubMed Web of Science ®Google Scholar
• MAAS B, KERR T, FAIRBAIRN N et al.: Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opin. Drug Metab. Toxicol. (2006) 2(4):533-543.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, WYNN HE, HEWITT RG et al.: Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J. Clin. Pharmacol. (2001) 41(4):435-442.
   PubMed Web of Science ®Google Scholar
• PENZAK SR, ACOSTA EP, TURNER M et al.: Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J. Clin. Pharmacol. (2002) 42(10):1165-1170.
   PubMed Web of Science ®Google Scholar
• LA PORTE C, VERWEIJ-VAN WISSEN C, VAN EWIJK N et al.: Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. J. Clin. Pharmacol. (2005) 45(2):211-218.
   PubMed Web of Science ®Google Scholar
• AARNOUTSE RE, GRINTJES KJ, TELGT DS et al.: The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin. Pharmacol. Ther. (2002) 71(1):57-67.
   PubMed Web of Science ®Google Scholar
• BOYD MA, AARNOUTSE RE, RUXRUNGTHAM K et al.: Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr. (2003) 34(2):134-139.
   PubMed Web of Science ®Google Scholar
• BURGER DM, PRINS JM, VAN DER ENDE ME et al.: The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID. J. Acquir. Immune Defic. Syndr. (2004) 35(1):97-98.
   PubMed Web of Science ®Google Scholar
• BURGER D, BOYD M, DUNCOMBE C et al.: Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J. Antimicrob. Chemother. (2003) 51(5):1231-1238.
   PubMed Web of Science ®Google Scholar
• CHOI JY, CHANG KH, PARK YS et al.: Pharmacokinetics of indinavir in Koreans and Caucasians. Scand J. Infect. Dis. (2004) 36(4):307-309.
   PubMed Web of Science ®Google Scholar
• BURGER DM, SIEBERS MC, HUGEN PW et al.: Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J. Acquir. Immune Defic. Syndr. (2002) 29(1):101-102.
   PubMed Web of Science ®Google Scholar
• FLETCHER CV, JIANG H, BRUNDAGE RC et al.: Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J. Infect. Dis. (2004) 189(7):1176-1184.
   PubMed Web of Science ®Google Scholar
• HAYASHI S, BECKERMAN K, HOMMA M et al.: Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS (2000) 14(8):1061-1062.
   PubMed Web of Science ®Google Scholar
• UNADKAT JD, WARA DW, HUGHES MD et al.: Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. (2007) 51(2):783-786.
   PubMed Web of Science ®Google Scholar
• KOSEL BW, BECKERMAN KP, HAYASHI S et al.: Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS (2003) 17(8):1195-1199.
   PubMed Web of Science ®Google Scholar
• GUARDIOLA JM, MANGUES MA, DOMINGO P et al.: Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure. AIDS (1998) 12(11):1395.
   PubMedGoogle Scholar
• OSTROP NJ, BURGESS E, GILL MJ: The use of antiretroviral agents in patients with renal insufficiency. AIDS Patient Care STDS (1999) 13(9):517-526.
   PubMed Web of Science ®Google Scholar
• BRODIE SB, KELLER MJ, EWENSTEIN BM et al.: Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS (1998) 12(18):2433-2437.
   PubMed Web of Science ®Google Scholar
• BOSSI P, PEYTAVIN G, LAMOTTE C et al.: High Indinavir Plasma Concentrations in HIV-1 Patients Co-infected with Hepatitis B or C Virus Receiving Indinavir and Ritonavir Low Dosages: A GENOPHAR Substudy. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 10 – 14 (2003):Abstract 546.
   Google Scholar
• DIELEMAN JP, SALAHUDDIN S, HSU YS et al.: Indinavir crystallization around the loop of henle: experimental evidence. J. Acquir. Immune Defic. Syndr. (2001) 28(1):9-13.
   PubMed Web of Science ®Google Scholar
• KOPP JB, MILLER KD, MICAN JA et al.: Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. (1997) 127(2):119-125.
   PubMed Web of Science ®Google Scholar
• REITER WJ, SCHON-PERNERSTORFER H, DORFINGER K et al.: Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J. Urol. (1999) 161(4):1082-1084.
   PubMed Web of Science ®Google Scholar
• SALTEL E, ANGEL JB, FUTTER NG et al.: Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J. Urol. (2000) 164(6):1895-1897.
   PubMed Web of Science ®Google Scholar
• HERMAN JS, IVES NJ, NELSON M et al.: Incidence and risk factors for the development of indinavir-associated renal complications. J. Antimicrob. Chemother. (2001) 48(3):355-360.
   PubMed Web of Science ®Google Scholar
• DIELEMAN JP, STURKENBOOM MC, JAMBROES M et al.: Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch. Intern. Med. (2002) 162(13):1493-1501.
   PubMed Web of Science ®Google Scholar
• HIRSCH MS, STEIGBIGEL RT, STASZEWSKI S et al.: Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. Clin. Infect. Dis. (2003) 37(8):1119-1124.
   PubMed Web of Science ®Google Scholar
• BOYD M, DUNCOMBE C, RUXRUNGTHAM K et al.: Indinvair TID versus indinvair/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pre-treated patients: Results of 76 Week follow-up. 9th Conference on Retroviruses and Opportunisitc Infection. Seattle, USA, February 24 – 28 (2002): Abstract 422-w.
   Google Scholar
• DIELEMAN JP, GYSSENS IC, VAN DER ENDE ME et al.: Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS (1999) 13(4):473-478.
   PubMed Web of Science ®Google Scholar
• BOYD MA, SIANGPHOE U, RUXRUNGTHAM K et al.: The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J. Antimicrob. Chemother. (2006) 57(6):1161-1167.
   PubMed Web of Science ®Google Scholar
• DUVIVIER C, MYRTO A, MARCELIN AG et al.: Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir. Ther. (2003) 8(6):603-609.
   PubMed Web of Science ®Google Scholar
• MOOTSIKAPUN P, CHETCHOTISAKD P, ANUNNATSIRI S et al.: Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts < 200 cells/mm3: 96-week outcomes. Antivir. Ther. (2005) 10(8):911-916.
   PubMed Web of Science ®Google Scholar
• BERNS JS, COHEN RM, SILVERMAN M et al.: Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am. J. Kidney Dis. (1997) 30(4):558-560.
   PubMed Web of Science ®Google Scholar
• WITTE M, TOBON A, GRUENENFELDER J et al.: Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis. J. Urol. (1998) 159(2):498-499.
   PubMed Web of Science ®Google Scholar
• CHEN SC, NANKIVELL BJ, DWYER DE: Indinavir-induced renal failure. AIDS (1998) 12(4):440-441.
   PubMed Web of Science ®Google Scholar
• HANABUSA H, TAGAMI H, HATAYA H: Renal atrophy associated with long-term treatment with indinavir. N. Engl. J. Med. (1999) 340(5):392-393.
   PubMed Web of Science ®Google Scholar
• KOPP JB, FALLOON J, FILIE A et al.: Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin. Infect. Dis. (2002) 34(8):1122-1128.
   PubMed Web of Science ®Google Scholar
• DIELEMAN JP, VAN DER FELTZ M, BANGMA CH et al.: Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection (2001) 29(4):232-233.
   PubMed Web of Science ®Google Scholar
• DIELEMAN JP, VAN ROSSUM AM, STRICKER BC et al.: Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J. Acquir. Immune Defic. Syndr. (2003) 32(2):135-142.
   PubMed Web of Science ®Google Scholar
• ZUCKER SD, QIN X, ROUSTER SD et al.: Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. USA (2001) 98(22):12671-12676.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12(7):F51-F58.
   PubMed Web of Science ®Google Scholar
• VIRABEN R, AQUILINA C: Indinavir-associated lipodystrophy. AIDS (1998) 12(6):F37-F39.
   PubMed Web of Science ®Google Scholar
• MILLER KD, JONES E, YANOVSKI JA et al.: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet (1998) 351(9106):871-875.
   PubMed Web of Science ®Google Scholar
• HERRY I, BERNARD L, DE TRUCHIS P et al.: Hypertrophy of the breasts in a patient treated with indinavir. Clin. Infect. Dis. (1997) 25(4):937-938.
   PubMed Web of Science ®Google Scholar
• NOOR MA, LO JC, MULLIGAN K et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 15(7):F11-F18.
   PubMed Web of Science ®Google Scholar
• ROJAS C, COPLAN PM, RHODES T et al.: Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. Pharmacoepidemiol. Drug Saf. (2003) 12(5):361-369.
   PubMed Web of Science ®Google Scholar
• BONFANTI P, VALSECCHI L, PARAZZINI F et al.: Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J. Acquir. Immune Defic. Syndr. (2000) 23(3):236-245.
   PubMed Web of Science ®Google Scholar
• FLORIDIA M, BUCCIARDINI R, FRAGOLA V et al.: Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (< 50 cells/microL). HIV Med. (2004) 5(1):1-10.
   PubMedGoogle Scholar
• GAJEWSKI LK, GRIMONE AJ, MELBOURNE KM et al.: Characterization of rash with indinavir in a national patient cohort. Ann. Pharmacother. (1999) 33(1):17-21.
   PubMed Web of Science ®Google Scholar
• TEIRA R, ZUBERO Z, MUNOZ J et al.: Stevens–Johnson syndrome caused by indinavir. Scand J. Infect. Dis. (1998) 30(6):634-635.
   PubMed Web of Science ®Google Scholar
• BOUSCARAT F, BOUCHARD C, BOUHOUR D: Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N. Engl. J. Med. (1998) 338(24):1776-1777.
   PubMed Web of Science ®Google Scholar
• ALAM M, SCHER RK: Indinavir-related recurrent paronychia and ingrown toenails. Cutis (1999) 64(4):277-278.
   PubMed Web of Science ®Google Scholar
• GARCIA-SILVA J, ALMAGRO M, PENA-PENABAD C et al.: Indinavir-induced retinoid-like effects: incidence, clinical features and management. Drug Saf. (2002) 25(14):993-1003.
   PubMed Web of Science ®Google Scholar
• FORNATARO K, JEFFERYS R: Crixivan side effect update – hair loss and ingrown toenails. Body Posit. (1999) 12(10):12.
   PubMedGoogle Scholar
• LENHARD JM, WEIEL JE, PAULIK MA et al.: Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. Biochem. Pharmacol. (2000) 59(9):1063-1068.
   PubMed Web of Science ®Google Scholar
• TOMA E, DEVOST D, CHOW LAN N et al.: HIV-protease inhibitors alter retinoic acid synthesis. AIDS (2001) 15(15):1979-1984.
   PubMed Web of Science ®Google Scholar
• RUTSTEIN RM, FEINGOLD A, MEISLICH D et al.: Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS (1997) 11(12):F107-F111.
   PubMed Web of Science ®Google Scholar
• KLINE MW, FLETCHER CV, HARRIS AT et al.: A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J. Pediatr. (1998) 132(3 Pt 1):543-546.
   PubMed Web of Science ®Google Scholar
• VIGANO A, DALLY L, BRICALLI D et al.: Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J. Pediatr. (1999) 135(6):675-682.
   PubMed Web of Science ®Google Scholar
• GULICK RM, MELLORS JW, HAVLIR D et al.: 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. (2000) 133(1):35-39.
   PubMed Web of Science ®Google Scholar
• HIRSCH M, STEIGBIGEL R, STASZEWSKI S et al.: A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J. Infect. Dis. (1999) 180(3):659-665.
   PubMed Web of Science ®Google Scholar
• BOYD MA, SRASUEBKUL P, KHONGPHATTANAYOTHIN M et al.: Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir. Ther. (2006) 11(2):223-232.
   PubMed Web of Science ®Google Scholar
• ARNAIZ JA, MALLOLAS J, PODZAMCZER D et al.: Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS (2003) 17(6):831-840.
   PubMed Web of Science ®Google Scholar
• KATNER HP, PAAR DP, NADLER JP et al.: Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. J. Acquir. Immune Defic. Syndr. (2002) 31(5):483-487.
   PubMed Web of Science ®Google Scholar
• JAYAWEERA DT, SCERPELLA E, ROBINSON M et al.: The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study. Int. J. STD AIDS (2003) 14(11):732-736.
   PubMed Web of Science ®Google Scholar
• DRAGSTED UB, GERSTOFT J, PEDERSEN C et al.: Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. (2003) 188(5):635-642.
   PubMed Web of Science ®Google Scholar
• PATEL AK, PATEL KK, PATEL JK et al.: Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-year follow-up. J. Acquir. Immune Defic. Syndr. (2006) 43(1):123-126.
   PubMed Web of Science ®Google Scholar
• JANKELEVICH S, MUELLER BU, MACKALL CL et al.: Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. J. Infect. Dis. (2001) 183(7):1116-1120.
   PubMed Web of Science ®Google Scholar
• National Guidelines for the Clinical Management of HIV Infection in Children and Adults. AIDS Division, Department of Communicable Disease Control, Ministry of Public Health, Nonthaburi, Thailand (2005).
   Google Scholar
• RAYNER CR, ESCH LD, WYNN HE et al.: Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen. Ann. Pharmacother. (2001) 35(11):1391-1395.
   PubMed Web of Science ®Google Scholar
• BURGER DM, HOETELMANS RM, HUGEN PW et al.: Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir. Ther. (1998) 3(4):215-220.
   PubMed Web of Science ®Google Scholar
• BURGER D, HUGEN P, REISS P et al.: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS (2003) 17(8):1157-1165.
   PubMed Web of Science ®Google Scholar
• RHAME FS, RAWLINS SL, PETRUSCHKE RA et al.: Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48(11):4200-4208.
   PubMed Web of Science ®Google Scholar
• LAMOTTE C, PEYTAVIN G, PERRE P et al.: Increasing Adverse Events (AE) with Indinavir (IDV) dosages and Plasma concentrations in Four Different Ritonavir (RTV)-IDV Containing Regimens in HIV-infected Patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 4 – 6 (2001): Abstract 738.
   Google Scholar
• BOYD M, MOOTSIKAPUN P, BURGER D et al.: Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir. Ther. (2005) 10(2):301-307.
   PubMed Web of Science ®Google Scholar
• BURGER DM, HUGEN PW, AARNOUTSE RE et al.: A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J. Acquir. Immune Defic. Syndr. (2001) 26(3):218-224.
   PubMed Web of Science ®Google Scholar
• BERGSHOEFF AS, FRAAIJ PL, VAN ROSSUM AM et al.: Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus Type 1-infected children. Antimicrob. Agents Chemother. (2004) 48(5):1904-1907.
   PubMed Web of Science ®Google Scholar